Vaccitech and Werewolf Therapeutics joined the public markets, raising a combined $230 million. The vaccine developer and the cancer immunotherapy biotech will apply the IPO proceeds toward clinical development of their respective pipelines.
The Series B round of funding for University of Oxford spinout Vaccitech includes the type of financial backers that could support an IPO. While Vaccitech might be best known for its association with AstraZeneca's Covid-19 vaccine, the startup also has programs for other infectious diseases and cancer.
In this episode hear how improving benefit verification, prior authorizations, and patient affordability with smart integrations and real-time eligibility can streamline healthcare workflows.